Co-treatment with BARD protected mice from this injury as demonstrated by the 64-fold and 72-fold higher urinary KIM-1 levels observed in Veh/CIS mice after 1 and 3–4 doses of cisplatin respectively, compared to BARD/CIS mice (Fig. 4A). The gene discussed is HAVCR1; the disease is in situ carcinoma.